Here's What's Behind Bristol Myers Squibb's Huge Acquisitions

The pharmaceutical industry is famous for generating enormous profits with help from patent-protected exclusivity, but those protections don't last forever. In order to produce steadily growing profits, Bristol Myers Squibb (NYSE: BMY) has been buying up drugmakers large and small.

In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Cory Renauer discuss Bristol Myers Squibb's recent purchase of MyoKardia (NASDAQ: MYOK) and its role in the company's overarching strategy.

Continue reading

Source Fool.com